Acumen Pharmaceuticals Has Dosed The First Subject With A Subcutaneous Formulation Of Sabirnetug (ACU193) In A Phase 1 Pharmacokinetic Comparison Study To Compare Subcutaneous And Intravenous Administrations Of Sabirnetug In Healthy Volunteers

Author: Benzinga Newsdesk | July 29, 2024 07:11am

Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs in AD patients. Soluble AβOs are a highly toxic form of Aβ that begin to accumulate before a clinical diagnosis of AD and are an early and persistent trigger of synaptic dysfunction and neurodegeneration. Acumen is developing sabirnetug as a potential next generation antibody treatment for early AD. The company is currently enrolling patients in the ALTITUDE-AD study, a Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of intravenous sabirnetug in patients with early AD.

Posted In: ABOS